This paper discusses scientific and policy issues related to vaccine platforms, and how they are understood in government, academia, and industry.
Although vaccines for the plague have been tried for decades, they have given only transient protection, and can’t protect against all forms of the plague, such as pneumonic plague.
Instead of using a single protein from the parasite, researchers are using entire parasites—which come with more than 5,000 proteins—deactivated with low doses of radiation.
The new technology allows researchers to quickly develop new vaccines, as well as tests able to distinguish between vaccinated animals and those infected.
The Uniformed Services University of the Health Sciences (USU), along with Profectus Biosciences, Inc., the Vanderbilt University Medical Center, Mapp Biopharmaceutical, Inc., and the University of Texas Medical Branch (UTMB), have been awarded up to $24.5 million to advance treatments for the highly lethal henipaviruses, Nipah and Hendra.
A concise network model developed by Washington State University researchers could help advance the understanding of disease-causing bacteria and guide vaccine development, such as for anaplasmosis in cattle.
In a move to defeat the next pandemic, the CEPI (Coalition for Epidemic Preparedness Innovations) has reportedly signed an agreement with CureVac, a German biopharmaceutical firm. The duo plan to develop a vaccine printing technology, with an aim to produce shots against various diseases.
The researchers add that the ability to manipulate live-attenuated Salmonella so that they express components of other pathogens could make their findings particularly exciting for future 'vector vaccine' design.
For the past 18 years, the World Vaccine Congress Washington congress has evolved and grown into the leading vaccines congress globally, with: 300 speakers, 1500 attendees and hundreds of networking opportunities.
The $8.4million project will develop technology to rapidly develop vaccines against known pathogens - such as flu, and unknown pathogens, called Disease X. The project will create a so-called self-amplifying RNA (saRNA) vaccine platform.